These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1031 related articles for article (PubMed ID: 25604608)

  • 1. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.
    McCombs JR; Owen SC
    AAPS J; 2015 Mar; 17(2):339-51. PubMed ID: 25604608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cleavable linkers in antibody-drug conjugates.
    Bargh JD; Isidro-Llobet A; Parker JS; Spring DR
    Chem Soc Rev; 2019 Aug; 48(16):4361-4374. PubMed ID: 31294429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physical and Chemical Stability of Antibody Drug Conjugates: Current Status.
    Ross PL; Wolfe JL
    J Pharm Sci; 2016 Feb; 105(2):391-397. PubMed ID: 26869406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
    Tsuchikama K; An Z
    Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates.
    Albers AE; Garofalo AW; Drake PM; Kudirka R; de Hart GW; Barfield RM; Baker J; Banas S; Rabuka D
    Eur J Med Chem; 2014 Dec; 88():3-9. PubMed ID: 25176286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned.
    López de Sá A; Díaz-Tejeiro C; Poyatos-Racionero E; Nieto-Jiménez C; Paniagua-Herranz L; Sanvicente A; Calvo E; Pérez-Segura P; Moreno V; Moris F; Ocana A
    J Hematol Oncol; 2023 Dec; 16(1):118. PubMed ID: 38087293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody drug conjugates.
    Bakhtiar R
    Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Drug Conjugates for Tumor Targeting-Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins.
    Merten H; Brandl F; Plückthun A; Zangemeister-Wittke U
    Bioconjug Chem; 2015 Nov; 26(11):2176-85. PubMed ID: 26086208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates.
    Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A
    J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates.
    Frigerio M; Kyle AF
    Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-drug conjugates- stability and formulation.
    Duerr C; Friess W
    Eur J Pharm Biopharm; 2019 Jun; 139():168-176. PubMed ID: 30940541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates.
    Puthenveetil S; Musto S; Loganzo F; Tumey LN; O'Donnell CJ; Graziani E
    Bioconjug Chem; 2016 Apr; 27(4):1030-9. PubMed ID: 26942771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.
    Singh SK; Luisi DL; Pak RH
    Pharm Res; 2015 Nov; 32(11):3541-71. PubMed ID: 25986175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current methods for the synthesis of homogeneous antibody-drug conjugates.
    Sochaj AM; Świderska KW; Otlewski J
    Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical de-conjugation for investigating the stability of small molecule drugs in antibody-drug conjugates.
    Chen T; Su D; Gruenhagen J; Gu C; Li Y; Yehl P; Chetwyn NP; Medley CD
    J Pharm Biomed Anal; 2016 Jan; 117():304-10. PubMed ID: 26406314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Conjugated Payload Measurement Using Enzymatic Release of Antibody-Drug Conjugate with Cleavable Linker.
    Rago B; Tumey LN; Wei C; Barletta F; Clark T; Hansel S; Han X
    Bioconjug Chem; 2017 Feb; 28(2):620-626. PubMed ID: 28140559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
    Chen H; Lin Z; Arnst KE; Miller DD; Li W
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.